Emerging Frontiers in AI for the Life Sciences
The hard part of writing about AI’s future in the life sciences is separating accumulated evidence from forecast. This chapter organizes seven directions by evidence status: demonstrated in partial form, theoretical but plausible, and beyond what current methods support. The goal is not prediction; it is a record of what the field could credibly claim in 2026.
Use this chapter to:
- Separate near-term frontiers from forecast-driven claims.
- Track the evidence needed for virtual cells, autonomous labs, multimodal models, and AI-designed interventions.
- Read frontier work against the handbook’s demonstrated, theoretical, and beyond-current-capability frame.
Summary: The frontiers in this chapter are not moving at the same speed. Virtual cells, autonomous discovery loops, multimodal biology models, AI-designed therapeutics, population-scale personalization, global access, and workforce change each need a different evidence standard.
Key point: A frontier is not a conclusion. The useful question is what would have to be true for the frontier to become routine practice, and whether that evidence exists today.
Bottom line: Track frontiers with the same discipline used for current systems: named conditions, prospective evidence, independent evaluation, and clear limits. Do not treat a forecast as a result.
What is this field trying to solve? Track frontier claims without turning forecasts into evidence.
What is the core idea? Classify each claim by current evidence and name the conditions that would have to hold for it to become routine practice.
What is the current state of the field? Virtual cells, autonomous discovery loops, multimodal biology models, and AI-designed interventions have partial demonstrations. None supports the full set of frontier outcomes often attributed to it.
What do we know, and what remains open? Bounded components can be evaluated today. End-to-end transfer, biological validation, operational reliability, and broad access remain open across multiple frontiers.
Why does this matter? Evidence tiers keep funding, research, and program decisions tied to demonstrated capability rather than forecast.
Introduction
The genre of “future of AI in [domain]” is unusually dangerous because it rewards confident prediction over calibrated uncertainty, and confident prediction in this field has a poor recent track record. The autonomous-driving timeline of the 2010s, the early clinical-AI deployments of the 2020s, and the recurring “drug discovery in two years” claims of every venture cycle should make any practitioner cautious about specific date predictions.
The structure is simple: separate what is happening, what could happen, and what should not yet be assumed. The chapter follows the project’s standard tier convention used in the Evaluation Principles chapter:
- Demonstrated frontiers have partial working evidence, not full delivery. They are the first areas to track.
- Theoretical frontiers are plausible from current evidence but have not yet been shown end to end. They are the most contested zone, where credible disagreement is healthy.
- Beyond current capabilities frontiers should be treated with deep skepticism. They may eventually materialise, but capability claims in this tier today are claims, not results.
The aim is calibration. A practitioner in 2026 should be able to read this chapter and know which frontiers to track, which to engage with, which to defer, and which to ignore. A practitioner in 2030 should be able to read this chapter and see, item by item, where the calibration was right and where it was wrong.
Demonstrated capability
Virtual cells (cell-type-specific)
A virtual cell is a computational model that predicts how a cell will respond to perturbations: drugs, genetic edits, signalling inputs, environmental changes. The community roadmap (Bunne et al., 2024) frames the virtual cell not as a single model but as a multi-scale, multi-modal predictive system: gene expression, protein activity, metabolism, signalling, structure, behaviour, all coupled. A Cell commentary frames the Virtual Cell Challenge as a shared benchmark, and the official results reported improvements on some metrics without a model consistently beating naive baselines across all metrics (Roohani et al., 2025; Arc Institute, 2025).
What exists in 2026: cell-type-specific perturbation models (Geneformer, scGPT, scFoundation lineage), pathway-specific simulation models, and several single-cell foundation models that capture useful representations across cell types. What does not exist: a general-purpose virtual cell that handles arbitrary perturbations on arbitrary cells with the reliability that AlphaFold 2 brought to structure prediction. The Perturbation Prediction and Virtual Cells chapter treats the current state in detail.
Mechanistic whole-cell modeling provides an important adjacent result. A 2026 Cell paper integrated genetic-information processing, metabolism, spatial organization, growth, and division to simulate the cell cycle of the minimal bacterium JCVI-syn3A (Thornburg et al., 2026). This is a bounded mechanistic model, not a general AI virtual cell. A separate Nature paper proposed a modular, agentic virtual-yeast architecture; it is a roadmap rather than a completed validation (Qian et al., 2026).
A general virtual cell would require broader perturbation data, integration across biological scales, and an evaluation regime that tests prospective transfer. Progress exists on each component, but the end-to-end capability is not established.
End-to-end autonomous discovery loops
A closed-loop discovery system proposes experiments via a model, executes them via robotic systems, analyses results via a model, and retrains. Materials science has working examples; biology has narrower ones (microbiome optimisation, enzyme engineering, certain antibody affinity maturation campaigns). The Self-Driving Laboratories and Agentic Science Workflows chapters track the current evidence.
What exists: autonomous loops in well-defined biological optimisation tasks. What does not exist: autonomous loops that produce clinically relevant biology without ongoing scientist supervision. The bottleneck is partly the integration of robotic execution with biological assays at clinical complexity, and partly the unsolved question of whether agentic systems make the kind of judgment calls that determine whether a piece of biology is interesting.
The evidence base supports closed-loop optimization in constrained experimental spaces. Ada, the mobile robotic chemist, and Coscientist provide hardware-coupled examples (MacLeod et al., 2020; Burger et al., 2020; Boiko et al., 2023). Virtual Lab, Co-Scientist, and Robin are adjacent agentic or lab-in-the-loop systems in which humans perform or authorize key experiments (Swanson et al., 2025; Gottweis et al., 2026; Ghareeb et al., 2026). A current review identifies scalability, generalizability, and provenance-complete experimentation as central infrastructure requirements for self-driving laboratories (Canty and Abolhasani, 2026).
What would have to be true: reliable, scalable assays for the biology in question; agents whose reasoning is auditable enough that scientists trust their experimental choices; institutional and regulatory frameworks that handle agent-led decisions at the lab level. The first is biology-bound; the second is AI-bound; the third is governance-bound.
Multi-modal biology foundation models
Current foundation models for biology mostly handle one modality at a time: sequence (ESM-2, ESM-3, Evo), structure (AlphaFold lineage), cells (Geneformer and successors), small molecules (various). AlphaFold 3 (Abramson et al., 2024), Boltz-2, and Chai-1 combine sequence, structure, and small-molecule chemistry; ESM-3 combines sequence, structure, and function annotations. LucaOne and ChatNT illustrate the nucleic-acid/protein bridge, with LucaOne framing a unified nucleic-acid and protein language model and ChatNT framing a conversational agent over DNA, RNA, and protein tasks (He et al., 2025; de Almeida et al., 2025).
What exists: working two- and three-modality models. What does not exist: a model that handles sequence, structure, cell, tissue, organism, and behaviour in one representation. Whether such a model is even desirable is contested; biology may benefit more from specialised models that interoperate than from one universal model.
What would have to be true: pre-training data that span the modalities with adequate coverage, architectures that handle scale heterogeneity across modalities, and evaluations that test integrated reasoning rather than per-modality performance. Some progress on all three is visible; convergence is not.
Theoretical capability
AI-designed therapeutics through regulatory approval
AI-associated candidates are in clinical trials. A 2024 analysis found early clinical-stage activity but cautioned that the evidence base was young and subject to selection effects (Jayatunga et al., 2024). Public evidence reviewed on August 12, 2026 did not identify an FDA- or EMA-approved small molecule whose molecular discovery was attributed to generative AI. This time-stamped negative must be rechecked as programs advance.
Translation depends on efficacy, safety, dose, manufacturability, clinical design, and regulatory evidence, regardless of how a candidate was discovered. AI can change selected early-stage tasks, but comparative evidence that it improves total cycle time, cost, attrition, or approval probability remains insufficient. The Translational Evidence and Failure Modes chapter treats the gap in detail.
What would have to be true: enough AI-derived candidates moving through trials to produce statistical evidence of improved success rates, regulatory frameworks that accept AI-derived data as primary evidence, and patient stratification approaches that exploit AI-derived precision in selecting who benefits. All three are plausible; none is yet established.
Personalised medicine at population scale
The vision is variant-level interpretation for every person in a population, integrated with phenotype and used to inform care. AlphaMissense scored approximately 71 million possible human single-amino-acid substitutions, categorizing 57% as likely benign, 32% as likely pathogenic, and 11% as ambiguous (Cheng et al., 2023). Those are model categories, not clinical classifications. Responsible-use reviews of polygenic risk scores warn that clinical utility, communication, and ancestry performance must be assessed before deployment (Polygenic Risk Score Task Force of the International Common Disease Alliance, 2021).
What does not exist: clinical-quality interpretation for most variants of unknown significance, integration of variant-level prediction with phenotype at the level of routine care, and the equity infrastructure to ensure that personalised medicine is not personalised only for those whose ancestry is over-represented in training data. The third is the under-discussed risk; AI personalisation built on a non-representative reference panel will entrench inequities, not narrow them (Sirugo et al., 2019; Martin et al., 2019).
What would have to be true: regulatory and clinical pathways for AI-generated variant interpretations to inform care; functional-validation data at scale to ground the predictions; reference data that represent global genetic diversity. Movement is visible on all three, slowly.
Global access narrowing or widening
In 2026, the question of whether AI in life sciences narrows global health inequities or widens them is genuinely open. The narrowing case: open-weight foundation models, accessible cloud compute, and shared benchmarks let well-resourced LMIC research groups operate near the global frontier on questions of local relevance (neglected diseases, regional pathogen surveillance, climate-driven health). The widening case: compute and data concentration in a small number of institutions creates a dependence on infrastructure most countries cannot replicate, and AI-personalised medicine built on under-representative reference data exports inequities that take decades to correct.
Both trajectories are visible. The outcome depends on policy and funding decisions more than on AI capability: open-data norms, compute access programmes, training pipelines for LMIC AI-in-biology researchers, and the way frontier labs handle data sovereignty. The Wiens et al. roadmap for responsible ML in healthcare (Wiens et al., 2019) and WHO’s health AI guidance frame the equity question for clinical AI and apply, with adjustments, to the broader life-sciences case (WHO, 2021).
What would have to be true for narrowing to win: sustained policy commitment to open-data and open-weight norms; targeted funding for LMIC AI-in-biology capacity; reference datasets that represent global diversity. None is automatic.
Workforce transition
Routine hypothesis generation, literature search, structural modelling, candidate ranking, and basic data analysis are increasingly AI-assisted. Wet-lab execution, experimental design judgment, and biological interpretation remain human-led. The net effect on the bio research workforce is uncertain. Plausible outcomes range from the most productive ten percent of researchers becoming substantially more productive (and the field consolidating around them) to a broader uplift in productivity that absorbs more biologists into AI-augmented roles than it displaces.
What would have to be true for the broader uplift outcome: education pathways that make AI tools second nature for the next generation of bench scientists; institutional reward structures that credit hybrid wet-dry-AI work; mid-career retraining that does not require leaving the field. The Workforce, Compute, and Institutional Readiness chapter covers the current state.
Beyond current capability
A single universal biology foundation model
The aspiration of one foundation model that handles sequence, structure, cell, tissue, organism, and behaviour in one representation is theoretical. A 2026 review describes generalist biological AI as a research direction while emphasizing data, biological complexity, scalability, and experimental validation (Rao et al., 2026). Universal-model claims should be evaluated against the exact modalities, tasks, and validation covered rather than the breadth of the label.
Fully autonomous wet-lab science without human judgment
Demos exist; reliable production science does not. The genre of “AI ran an experiment and discovered” headlines mostly describes constrained optimisation in materials or microbiology, not open-ended scientific discovery. A general AI scientist that proposes meaningful biology, runs the right experiments, and interprets the results without scientist supervision is beyond current capabilities. Claims to the contrary should be evaluated against what an independent group reproduced, not against what a single team demonstrated under controlled conditions.
One-decade prediction of which AI will be dominant
The current architectures (transformers in various forms, diffusion models for generation) have been dominant for less than a decade. The history chapter shows that each prior decade’s dominant architecture was largely unanticipated by the prior decade’s practitioners. Claims that the current generation will still be dominant in 2036 should be evaluated against this prior, not on the strength of present momentum.
Evidence that would change the assessment
Frontiers become more promising when they move from isolated demonstrations to repeated prospective results under independent evaluation. For this chapter, the strongest signal would be a frontier satisfying its named conditions: virtual-cell perturbation prediction across cell types, autonomous loops that reproduce across labs, AI-designed therapeutics with Phase 3 success, or population-scale variant interpretation with equitable performance.
Implications for research and program decisions
Decisions today that hold up across most futures:
- Build on durable foundations, not on the current generation’s architectures. The functions (structure prediction, perturbation modelling, sequence search, generative design) will outlast the named systems. Invest in the workflow patterns, not the brand-name tool.
- Choose frontiers to track explicitly. A laboratory cannot engage with every frontier. Two or three should be selected to match the scientific question and the next-five-year roadmap, then tracked with the same discipline applied to established work.
- Engage at the partially demonstrated frontier, not at the theoretical or beyond-current frontier. Working with virtual-cell methods for a defined cell type, autonomous loops for a defined assay class, or multimodal models for a defined modality is reasonable. Building a programme around fully autonomous science or universal foundation models is not.
- Insist on the same evidence discipline for forward-looking claims as for retrospective ones. The Evaluation Principles chapter applies to “we are about to do X” as much as to “we have done X.” Use task-appropriate blind evaluation, biology-aware splits, prospective validation, and transparent reporting.
- Read the equity question explicitly. Personalised medicine, global access, and workforce questions are not subsidiary to the technical frontiers; they are the questions that determine whether the technical frontiers produce broad benefit or concentrate it.
- Use this chapter as a timestamp. In 2030, note which frontiers materialised, which stalled, and which collapsed into hype. The exercise calibrates judgment about the next round.